Longevity
Kidney protection from GLP-1 and SGLT-2 drugs depends on one blood marker
By Life and Health Today Staff, . Life and Health Today.
Two of the most-talked-about drug classes in metabolic medicine, GLP-1 receptor agonists (drugs that mimic a gut hormone to lower blood sugar and, in some cases, body weight, including semaglutide-based medications) and SGLT-2 inhibitors (drugs that make the kidneys excrete excess glucose in urine), protect kidney function in people with type 2 diabetes, but only when a specific warning sign is already present in the urine. That is the central finding of a target trial emulation published in BMJ (Clinical research ed.), drawing on linked electronic health records and insurance claims from 10 health systems and two national health insurance plans, as part of the BESTMED study.
The study enrolled 75,455 people with type 2 diabetes who were taking metformin and then added a second medication between 2014 and 2022. Researchers compared those who started a GLP-1 receptor agonist or SGLT-2 inhibitor against those who started a DPP-4 inhibitor, an older, well-established second-line diabetes drug, and followed them for a median of 32 months.
The warning sign at the center of the finding is albuminuria: the presence of albumin, a protein, in the urine at a ratio of 30 milligrams per gram of creatinine or higher. Albumin leaking into urine is an early signal that the kidneys' filtering system is under strain. About 18% of the study population had it.
Among people with albuminuria, the estimated five-year risk of serious kidney deterioration, defined as a doubling of a waste-product marker in the blood called serum creatinine, or a steep drop in the kidney's estimated filtering rate, was 3.2% for those on GLP-1 or SGLT-2 drugs, compared with 5.4% for those on DPP-4 inhibitors. That translates to a risk ratio of 0.60, meaning roughly 40% lower relative risk. In absolute terms, that is a difference of about 2.2 percentage points over five years in this population.
Among the 81% of participants without albuminuria, the picture was different. The five-year risk was 2.4% on GLP-1 or SGLT-2 drugs versus 2.1% on DPP-4 inhibitors, a risk ratio of 1.10, with a confidence interval spanning 0.90 to 1.38. That range crosses 1.0, meaning the researchers could not rule out no difference at all. The BMJ study's authors concluded there was "little evidence of renal benefit among people without albuminuria" over the follow-up period.
A target trial emulation is an observational method that tries to mimic what a randomized controlled trial would look like, using real-world records rather than randomly assigning patients to treatments. It is a rigorous design, but it is not a randomized trial. People were not randomly assigned to drugs; their doctors chose. That means unmeasured differences between groups, sicker patients steered toward one drug, for instance, could still influence the results, even after statistical adjustment.
What this does not show is whether the same pattern holds for people at different stages of kidney disease, different cardiovascular risk profiles, or on different specific drugs within each class. The study grouped GLP-1 receptor agonists and SGLT-2 inhibitors together rather than comparing them head-to-head, so it cannot say whether one class drives more of the benefit than the other among patients with albuminuria.
The open question for a reader on one of these medications is straightforward: has your urine been tested for albumin? If it has not, this study suggests that is the test most likely to tell you whether kidney protection is something you are already getting. That conversation belongs with a clinician who knows your full history, not a supplement stack or a protocol.
For context, the US Bureau of Labor Statistics reported that prices for medical goods, including drugs and supplies, fell 2.7% year on year as of August 2026. That does not change what the study found, but it is worth noting for anyone weighing the cost of staying on a newer drug class versus switching.